A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study with a Long-Term Extension Treatment Period to Assess the Efficacy and Safety of JNJ-63733657, an Anti-tau Monoclonal Antibody, in Participants with Early Alzheimer's Disease

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-501188-42-00

Acronym

63733657ALZ2002

Enrollment

195

Registered

2022-11-11

Start date

2021-04-15

Completion date

Unknown

Last updated

2025-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Early Alzheimer's Disease

Brief summary

Change from baseline on the iADRS total score at week 104

Interventions

DRUGPL1

DRUGJNJ-63733657

DRUGflorquinitau F18

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Change from baseline on the iADRS total score at week 104	—

Countries

Belgium, France, Netherlands, Spain, Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026